SCHEMBL7666399

SCHEMBL7666399

CCCCn1cnc2c(OCCOC)nc(Nc3cnc4ccccc4c3)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 6/20 0.40
▸ PDGFRA P16234 4/20 0.40
▸ CCNE1 P24864 4/20 0.40
▸ LMNA P02545 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CLK4 Q9HAZ1 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ IGF1R P08069 8/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ TRPV1 Q8NER1 4/20 0.38
▸ EGFR P00533 2/20 0.37
▸ INSR P06213 2/20 0.37
▸ MET P08581 2/20 0.37
▸ KDR P35968 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7666193 0.94 CDK2 (0.41) CDK2PDGFRACCNE1LMNAIGF1R
SCHEMBL7666197 0.91 CDK2 (0.40) CDK2PDGFRACCNE1LMNAIGF1R
SCHEMBL7664310 0.91 CDK2 (0.42) CDK2PDGFRACCNE1LMNAIGF1R
SCHEMBL7670174 0.88 CDK2 (0.40) CDK2PDGFRACCNE1LMNAIGF1R
SCHEMBL7661378 0.87 CCNE1 (0.51) CDK2PDGFRACCNE1LMNACYP1A2
SCHEMBL7672070 0.87 CDK2 (0.41) CDK2PDGFRACCNE1LMNAIGF1R
SCHEMBL7668416 0.86 CCNE1 (0.41) CDK2PDGFRACCNE1LMNAIGF1R
SCHEMBL7672349 0.85 SLC29A1 (0.43) CDK2PDGFRACCNE1CYP1A2IGF1R
SCHEMBL7357728 0.83 CTSL (0.43) CDK2PDGFRACCNE1
SCHEMBL7661510 0.83 PDGFRA (0.41) CDK2PDGFRACCNE1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6414147-B1 DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY NEUROGEN CORPORATION 2002-07-02 — — US claimed
US-6414147-B1 DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY NEUROGEN CORPORATION 2002-07-02 — — US disclosed
Send feedback